The publisher explores Biogen’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (21 October 2020)
Model updates (22 July 2020)
Model updates (22 April 2020)
Model updates (30 January 2020)
Snapshot
- Overview - Biogen’s prescription pharmaceutical business will see stable performance over the medium term.
- Key themes - [1] Biogen’s flagship MS portfolio - Tecfidera, Avonex, Plegridy, and Tysabri - remains incredibly stable [2] Spinraza revenues will plateau during the forecast period due to competition from newer products [3] Biogen’s revival of aducanumab is a surprise and will add significant revenue during the forecast period.
Model updates (21 October 2020)
- Tecfidera forecast adjusted lower due to generic competition in the US
- Spinraza forecast adjusted lower due to competition in the US
- Vumerity forecast adjusted higher due to better launch trend in the US
- Aducanumab forecast adjusted higher due to refinement of Alzheimer’s disease market potential and launch trends.
Model updates (22 July 2020)
- Tecfidera forecast adjusted significantly lower due to litigation outcome resulting in earlier generic competition
- Vumerity forecast adjusted lower due to later expected launch in EU and RoW
- Imraldi forecast adjusted lower in EU.
Model updates (22 April 2020)
- Vumerity forecast adjusted lower due to continued slow launch.
Model updates (30 January 2020)
- Spinraza forecast adjusted higher due to continued international growth
- Avonex forecast adjusted lower due to continued competition in multiple sclerosis
- Vumerity forecast adjusted lower due to initial launch trends.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
